Phaseline

Companies › NovaGo Therapeutics

NovaGo Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 1; Neurology; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NG004–Phase 1Acute Spinal Cord Injury (SCI)Mar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06817577NG004Phase 1Acute Spinal Cord Injury (SCI)NeurologyMar 2027
NCT07840196NG004Phase 1Acute Spinal Cord Injury (SCI)NeurologyJul 2029

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.